Kiniksa Pharmaceuticals International (KNSA) Net Cash Flow (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Net Cash Flow for 10 years, with the latest figure at $24.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 192.09% year-over-year to $24.4 million; the trailing twelve-month figure through Mar 2026 stood at $32.8 million (up 104.44% YoY), and the FY2025 full-year result was -$18.0 million, down 123.78% from the prior year.
• Net Cash Flow for Q1 2026 stood at $24.4 million, up from -$9.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $86.2 million in Q4 2024, with the low at -$59.1 million in Q1 2022.
• Historically, Net Cash Flow has averaged $4.0 million across 5 years, with a median of -$1.9 million in 2024.
• Annual changes were most pronounced in 2022 — Net Cash Flow plunged 1116.6% — and 2024, when it jumped 973.05%.
• Kiniksa Pharmaceuticals International's Net Cash Flow stood at -$53.0 million in 2022, then soared by 81.39% to -$9.9 million in 2023, then jumped by 973.05% to $86.2 million in 2024, then slumped by 110.74% to -$9.3 million in 2025, then surged by 362.97% to $24.4 million in 2026.
• The last three Net Cash Flow figures came in at $24.4 million (Q1 2026), -$9.3 million (Q4 2025), and -$17.2 million (Q3 2025), per Business Quant data.